from The Epoch Times:
CDC officials are investigating a potential link between two recently approved RSV vaccines and increased reports of Guillain-Barré syndrome in adults over 60.
Recently approved vaccines for respiratory syncytial virus (RSV) for older adults may be linked to a rare nervous system disorder that causes the body’s immune system to attack its own nerves.
TRUTH LIVES on at https://sgtreport.tv/
The FDA uses data mining to identify statistical associations between products and events in their respective safety databases. If there is disproportionate reporting of an event for a particular product, this could suggest a statistical association between the adverse event and the product.
According to data from the Vaccine Adverse Event Reporting System (VAERS) presented by Dr. Shimabukuro, data show 35 reports of GBS with 18 cases attributed to Pfizer’s vaccine, Abrysvo, 16 cases attributed to GSK’s Arexvy, and one case that was not reported under either brand name.
The CDC verified 23 cases of GBS reported to VAERS as of Feb. 16—all occurring within 22 days of RSV vaccination. Of the 23 cases, 15 were attributed to Pfizer’s vaccine and eight to GSK’s vaccine. Fourteen males experienced the condition compared with nine females. There was one death reported in a 70-year-old man who developed GBS after receiving Arexvy.
“Certainly 23 cases of GBS within 22 [days] of RSV vaccination is not a ‘small signal’ given the woeful underreporting in VAERS,” Brian Hooker, chief scientific officer at Children’s Health Defense, who holds a doctorate in biochemical engineering, told The Epoch Times in an email.
